New Zealand’s a2 Milk full-year profit rises 21%

a2 Milk Co reported a 21.1% increase in full-year net profit to NZ$202.9 million, marginally exceeding consensus estimates, primarily driven by strong infant milk formula sales in its key China and Asian markets, which rose nearly 14% to NZ$1.3 billion. This growth was achieved through effective marketing and improved brand health, even amidst declining birth rates in China. The company also announced strategic moves to acquire Yashili New Zealand for China-label product registrations and divest Mataura Valley Milk, with plans for a NZ$300 million special dividend upon the completion of these transactions.

Analysis

a2 Milk Co demonstrated robust financial health, reporting a 21.1% increase in full-year net profit to NZ$202.9 million, which marginally surpassed Visible Alpha consensus estimates. This performance was primarily fueled by significant momentum in its key China and other Asian markets, where infant milk formula sales surged nearly 14% to NZ$1.3 billion. The company successfully navigated the headwind of declining birth rates in China through effective marketing and enhanced brand metrics, leading to a 12.4% overall jump in infant formula sales. Concurrently, management is executing a strategic portfolio realignment by acquiring the Yashili New Zealand manufacturing facility, which provides crucial China-label product registrations, while divesting Mataura Valley Milk. This strategic activity is paired with a strong commitment to shareholder returns, evidenced by a final dividend and a planned NZ$300 million special dividend contingent on the completion of these transactions.

Key Decisions for Investors

• The strong earnings beat and successful growth in the challenging China market provide a solid basis for a positive outlook on the company's operational execution and brand strength.
• Investors should closely monitor the execution and timeline of the Yashili acquisition and Mataura divestment, as the material NZ$300 million special dividend is conditional upon the completion of these deals.
• While the results are strong, the underlying demographic pressure from declining birth rates in China remains a key long-term risk factor, making continued market share gains essential for future growth.